LB766 Prevalence and adverse events of special interest among COVID19-vaccinated patients with chronic inflammatory skin diseases: An early look

Raiker, R.; Pakhchanian, H.; Hochman, E.; Russomanno, K.; Deng, M.

Despite increasing rates of COVID-19 vaccination among those living in the United States, there is little known about the prevalence of vaccination among patients with chronic inflammatory skin diseases and if any significant adverse reactions have occurred within these specific groups. The goal of this study was to further analyze these trends. A retrospective analysis was conducted from December 2020 to March 2021 using TriNetX, a national federated, real time database of 69 million records. The prevalence of COVID-19 vaccination among patients with inflammatory skin diseases including psoriasis (Pso), atopic dermatitis (AD), and hidradenitis suppurativa (HS) was calculated. A 1:1 matched propensity score analysis was then conducted, adjusting for comorbidities and demographics, to generate adjusted risk ratios (aRR) with 95% CI. The outcome was any adverse event of special interest (AESI), as defined by the CDC and FDA, that occurred at any point after vaccination. In a sample of 301,878 patients who were vaccinated,1.5% had Pso, 1.4% had AD, and 0.3% had HS. After matching, cases had no significant differences compared to controls for any AESIs after either the first dose (Pso: 1.1[0.5-2.3], AD: 1.4[0.7-2.8], HS:1.0[0.4-2.4]) or second dose of vaccine (Pso: 1.4[0.7-2.7], AD: 1.0[0.6-1.7], HS: 1.0[0.4-2.4]). Matched subgroup analysis among the two major COVID-19 vaccine brands also revealed no differences in AESIs among Pso, AD, and HS patients. While preliminary, the current data reveals that patients with chronic inflammatory skin diseases are not at higher risk of any AESIs after receiving the COVID-19 vaccine. Further studies are warranted to continuously evaluate the trends in side effect profiles of these vaccines.